Resistance taiāki huka - he aha te mea te reira? Ko te syndrome pūkoro he taiāki resistance

Hoki te iwi rerekē te āhuatanga e rerekē kaha o te taiāki ki whakaongaonga hāpainga kūhuka. He mea nui ki te mohio e taea whai i te tūtohutanga noa ki tetahi atu ranei o nga pānga o te pūhui, me i te wa ano i te tangata - he ātete tino ki te tahi atu. Next, tātari tatou te ariā o "ātete taiāki": he aha te mea te reira, me pehea te whakaaturia i te reira.

Overview

I mua e pā ana ki te ariā o "ātete taiāki", he aha te mea te reira me te mea huanga mahi, me mea te reira e kore te mea nohinohi tenei mate. Neke atu i te 50% o te iwi ki te takawhita mamae i tenei mate. Nuinga o ngā wā, ka kitea taiāki resistance (i te mea te reira, ka kia whakaahuatia i raro nei) e i roto i te paari. Otiia i roto i ētahi wā e kitea ana e ia i roto i te tamarikitanga. taiāki resistance syndrome kore e maha kitea i mua, e kore e timata i te reira ki te whakaatu i te takahi o ngā tukanga pūkoro tinana. Te hunga i te mōrearea ngā iwi ki dyslipidemia ranei kātakí kūhuka waimaero, mōmona, takawhita.

resistance taiāki

He aha te mea te reira? He aha ngā āhuatanga e te ofatiraa? syndrome pūkoro o te taiāki huka resistance ko te whakautu hē o te kaiao ki te mahi o tetahi o nga pūhui. Ko te hāngai ki rerekē pānga koiora te ariā. Tenei, i roto i ngā, pā ana ki te mana o te taiāki huka i runga i te pūmua me te lipid ka pākia, te whakaaturanga ira, te mahi iaia endothelial. arata'i whakautu waimaero ki te hua i roto i te kukū toto o te pūhui e hiahiatia ana ki te rōrahi whanaunga kūhuka e wātea ana. taiāki syndrome resistance - he mate ngā. whai wāhi te reira i te tauiraa i roto i te kātakí kūhuka, momo 2 mate huka, dyslipidemia, te mōmonatanga. "Syndrome X" me tā hoki te ātete ärai o te kūhuka (taiāki huka-ti'aturi).

whanaketanga tikanga

Fully tūhura ona tohunga ki rahua rā. Disorders e arahi ki te whanaketanga o te taiāki huka resistance kia puta i te taumata e whai ake nei:

• Receptor. I roto i tenei take, te āhua e whakaaturia pakuwha heke ranei i roto i te maha o receptors.
• I te taumata o te waka kūhuka. I roto i tenei take, te heke o ngā rāpoi ngota GLUT4 kitea.
• Mua-receptoral. I roto i tenei take korero tatou e pā ana ki te taiāki huka rerekē.
• Postreceptor. I roto i tenei take i reira ko te phosphorylation takahi me te tauwhatinga o te tuku tohu.

E makona onge abnormalities o ngā rāpoi ngota taiāki me kahore auraa haumanu. kia heke receptor kiato i roto i tūroro e tika ana ki te urupare tōraro. Ko reira e tika ana ki te hyperinsulinemia. E mea pinepine, tūroro i te heke i roto i ngā tau receptor tika. I roto i tenei take, e kore e te taumata urupare whakaaro he paearu e nei te mea i whakaritea ki ta tohu he taiāki resistance. E iti ana te take o te whakararuraru, e tohunga ki te postreceptor maumaui tuku. Na roto i te precipitating āhuatanga, i roto i ngā, ngā:

• Smoking.
• tirotiro TNF-Arepa nui ake.
• Whakaero mahi tinana.
• Te whakanui ake i ngä nohanga o waikawa ngako kore-esterified.
• Age.

Ko nga āhuatanga matua e taea tīmata taiāki ātete atu pinepine atu i ētahi atu enei. Kei roto Treatment te tono:

• Thiazide rōpū Diuretics.
• blockers Beta-adrenergic.
• waikawa Nicotinic.
• Corticosteroids.

resistance taiāki nui haere

Pānga i runga i pākia kūhuka i puta i roto i te kiko adipose, uaua, me te ate. uaua kōhiwi metabolizes āhua 80% o te pūhui. Ko te uaua i roto i tenei take mahi hei puna nui o te taiāki resistance. kawea Tuhinga o te kūhuka i te pūtau kei te roto e te tikanga o te pūmua waka GLUT4 motuhake. A, no te whakahohe te receptor e taiāki huka rongo te raupapa o tauhohe phosphorylation. Ratou pae hopea hua i roto i te translocation o GLUT4 ki te membrane pūtau i te cytosol. Mai te kūhuka e taea ki te tomo i te pūtau. Taiāki resistance (ka auau e tohua ake nei) meinga e te hekenga i roto i te tohu o te translocation o GLUT4. Kei te kï hoki, te iti iho i roto i te whakamahi, me te whakamahinga kūhuka. Te taha ki tenei, haunga ngä hopu o te kūhuka i roto i te kopa piringa, ka tāmia hyperinsulinemia te hanga kūhuka ate. I roto i te momo 2 mate huka e anō reira.

mōmona

Kei te ngā reira ki te ātete taiāki maha nui. A, no te rawa manawanui taimaha 35-40% tūtohutanga makaka e 40%. Kei roto i te puku taiepa kiko ngako he mahi pūkoro runga ake i te kotahi kei nei te raro nei. I roto i ngā kitenga hauora whakakitea e rahi tuku ki te waikawa ngakongako tomokanga tohanga i muka puku whakaoho hanga o ngā pāhare ate.

tohu haumanu

Taiāki ātete, e tohu e pā ana ki raruraru pūkoro kia pai io e whakapae i roto i te tūroro ki te mōmona puku, mate huka gestational, he aamu utuafare o te momo 2 mate huka, dyslipidemia me takawhita. I mōrea me nga wahine ki te syndrome kura kākano polycystic (PCOS). Nā ki te meka e mahi mōmona rite te tohu o te taiāki ātete, he mea e tika ana ki te arotake i te āhua, i runga i nei i reira ko te tohatoha o te kiko adipose. Ka taea te ginekoidnomu Ko tōna wāhi - i roto i te wahi o raro o te tinana, momo humanoid ranei - i roto i te taiepa mua o te peritoneum. Haaputuraa i roto i te hawhe o runga o te tinana he kaimatapae atu nui o taiāki ātete, rereke kātakí kūhuka me mate huka, te mōmona atu te wahi o raro. I roto i te tikanga ki te tautuhi i te nui o puku kiko ngako taea te whakamahi i te tikanga e whai ake nei: ki te whakatau i te ōwehenga o te hope paenga, hip paenga me BMI. I reiti o 0.8 mō wahine me te 0.1 mō te tangata me he BMI nui ake i 27 e pāngia ki te mōmona puku, me te taiāki huka resistance. whakakitea mate tohumate waho. I roto i ngā i runga i te kiri tohua mingimingi, ngā wāhi hyperpigmented taratara. Nuinga o ngā wā puta ratou i roto i te peke, nga tuke, i raro i nga uma. Tātaritanga o taiāki resistance ko te tātai tātaitanga. tatau Homa-IR te e whai ake: nohopuku taiāki huka (MU / L) x te kūhuka i nohopuku (mmol / L). wehea te hua whiwhi e 22.5. ka whai i taua taiāki resistance taupū. Norma - <2,77. A, no te taea te pāngia te ine i roto i te ahunga o te whakanui ake tūtohutanga te kopa whakararuraru.

Disorders o te tahi atu pūnaha: atherosclerosis

I teie mahana i reira he kore whakamārama kotahi mō te huarahi o mana insulinorezistenotnosti te hinga o te pūnaha Cardiovascular. He pea he pānga tika i runga i atherogenesis. Kei te meinga te reira e te kaha o te taiāki huka ki te whakaongaonga i te ariā o lipids me ngā wāhanga o te tini o te uaua maeneene i roto i te taiepa oko. Me ki tenei kia meinga e arteriosclerosis e pā ana disorders pūkoro tinana. Hei tauira, kia mau ai ki takawhita, dyslipidemia, huringa i roto i te kātakí kūhuka. I roto i te pathogenesis o te mate, ko te o ngā faufaa waimaero mahi o te endothelium iaia. Ko tōna mahi ko ki te pupuri i te āhua o takere toto na roto i te secreting neurotransmitters vasodilation me vasoconstriction. I roto i te kāwanatanga ture taiāki whakaongaonga whakangā o te muka uaua maeneene o te taiepa oko na te tuku waikura nitric (2). Ano, tona kaha ki te whakarei ake vasodilation endothelium-ti'aturi tino puta i roto i te tūroro ki te mōmona. Ko te taua pā ki tūroro ki taiāki resistance. Ki te whanaketanga o te kore te AVC ki te urupare ki akiaki noa, a ka ki te whakawhānui, ka taea e koe te kōrero e pā ana ki te wā tuatahi o disorders microcirculatory - microangiopathy. kitea ana tēnei huru pathological te i roto i te nuinga o te tūroro ki te mate huka (mate huka mellitus).

Ka taea e taiāki ātete meinga atherosclerosis e raruraru i roto i te tukanga o te fibrinolysis. Pai-1 (plasminogen activator inhibitor) kei roto i nohanga tiketike i roto i ngā tūroro mate huka, me te nondiabetic mōmoma. Synthesis o Pai-1 whakaongaongatia proinsulin me te taiāki. nui haere hoki te taumata o te pūtaitoto me ētahi atu āhuatanga procoagulant.

Rereke kātakí kūhuka me momo 2 huka

Taiāki resistance ko te take i mua ki te whakakitenga haumanu o mate huka. Hoki te whakaiti i te kukū o te kūhuka te whakatau i te pūtau beta i roto i te repe taiaki. Whakaiti i te kukū kawea i roto i te whakanui ake i te hanga o te taiāki huka, i roto i te tahuri arata'i ki te hyperinsulinemia whanaunga. Ka taea te tonu Euglycemia i roto i tūroro rite te roa rite te pūtau beta e taea ki te mau tonu ngā taumata āhua teitei o te wē taiāki ki te hinga i te parenga. I te pae hopea, e ngaro tenei kaha, a ka whakanuia ana te kukū o te kūhuka tino. He take matua, i te kawenga mō te Hyperglycemia i runga i te puku kau i runga i te whakamārama o te momo 2 mate huka, taiāki resistance ko te ate. whakautu Healthy ko ki te whakaiti i production kūhuka. A, no te taiāki ātete, ngaro te urupare te. Ka rite ki te hua, tonu nui production ate kūhuka i, hua i roto i te nohopuku Hyperglycemia. Ki te mate o te kaha o ngā pūtau beta ki te whakarato i taiāki hypersecretion tohu te whakawhitinga i te taiāki ātete ki hyperinsulinemia ki kātakí kūhuka rereke. I muri, kua puta te kāwanatanga ki te mate huka haumanu me te Hyperglycemia.

takawhita

He maha ngā tikanga e arahi ki tona whanaketanga i runga i te whakamārama o te taiāki huka resistance. whakaatu kitenga e kia whai wāhi te vaivai o te vasodilation me vasoconstriction whakahohenga ki ātete iaia. whakatairanga taiāki pūnaha io whakaongaonga (pukuaroha). arata'i tenei ki te hua i roto i te wē norepinephrine kukū. I roto i te tūroro ki te taiāki ātete nui haere whakautu ki angiotensin. I tua atu, e taea te takahi whakaritenga vasodilation. Ko te taiāki huka ture āhua whakaongaonga whakangā o te taiepa uaua iaia. takawaenga Vasodilatation i roto i tenei take e te tukunga / whakatupuranga o waikura nitric endothelial. I roto i te tūroro ki te taiāki ātete, waimaero mahi endothelial te. te whakaiti i tenei te vasodilation e 40-50%.

dyslipidemia

A, no te aukati taiāki resistance noa putanga pehanga fatty waikawa noa i muri i te kai i te kiko adipose. kukū nui haere hua he tïpako mo te kōtuitui whakarei o pāhare. Ko te taahiraa nui i roto i VLDL production tenei. A, no te hyperinsulinemia iti mahi o te nui paru - lipase lipoprotein. I roto i te huringa kounga i roto i te papamuri tūāwhiorangi momo LDL 2 mate huka, me te taiāki huka ātete kia whakahuatia nui ake tohu o te piti hāora o matūriki LDL. More haria ki tenei tukanga whakaaro e apolipoproteins glycated.

mehua haumanu

Ka taea e te whakanui ake taiāki tūtohutanga kia tutuki i roto i te maha ngā huarahi. O te faufaa ngā ko te whakaiti i roto i te taimaha me te mahi tinana. He nui hoki te iwi nei e pāngia ki te taiāki ātete hoki Diet. whai wāhi Diet ki stabilization i roto i te torutoru ra. Whakarei tūtohutanga atu e whakatairanga mate taimaha. No te iwi ki te ātete taiāki fakapapau'i, ngā maimoatanga o te maha ngā wāhanga. whakaaro stabilization o kai, me te tinana mahi te ki hei te wā maimoatanga tuatahi. No te iwi e Kua tāutuhia taiāki, kia waiho te kai iti-pūngoi. maha tauturu te hekenga āhua i roto i te taimaha tinana (5-10 kirokaramu) ki te whakapai ake i te mana o ngā taumata kūhuka. tohaina Calories 80-90% te i waenganui i te warowaihā me te ngako, 10-20% i pūmua.

rongoā

Tikanga "Metamorfin" e pā ana ki te rōpū o ngā rongoā biguanide. whakapiki i te raau i te tūtohutanga taiāki piringa, me te ate. I roto i tenei take te tikanga e kore e pānga i runga i tona secretion. I roto i te ngaro o te faaineineraa taiāki "Metamorfin" hua. Tikanga "Troglitazone" Ko te rōpū tiazolidinedionov medicament tuatahi tukua nei te ki te whakamahi i roto i te USA. faarahi te tarukino te waka o te kūhuka. Kei te pea meinga tenei i te whakahohenga o PPAR-gamma receptor. Na reira whakarei GLUT4 faaiteraa, e i roto i te tahuri arata'i ki te hua i roto i te hopu kūhuka taiāki-whakaongaonga. No te tūroro e whai he ātete taiāki, e taea te whakahaere me te ngā maimoatanga. Ka taea te whakamahi i te tikanga i runga ake i roto i ngā ki te sulfonylurea, a ki ia atu ētahi wā ki te whakaputa i te pānga synergistic i runga i wē kūhuka me ētahi atu disorders. Ko te tarukino "Metamorfin" i roto i ngā ki te sulfonylurea faarahi secretion me taiāki tūtohutanga. I roto i tenei take, taumata kūhuka iti i muri i ngā kai, me te i runga i te puku kau. Tūroro e kua whakaritea te maimoatanga ngā, i mau faaiteraa atu noa o e suka.